Venetoclax

3 articles published between May 13, 2026 and September 3, 2026.

WHAT THE STUDY ACTUALLY SAYS

A gentler drug pair beat intensive chemo on one measure in fit leukaemia patients

In the 172-patient PARADIGM trial, azacitidine plus venetoclax more than doubled median event-free survival versus induction chemotherapy — but it was a phase 2 study not powered for overall survival.

3 min read

WHAT THE STUDY ACTUALLY SAYS

Pirtobrutinib added to venetoclax-rituximab slows relapse in treated CLL

In the phase 3 BRUIN CLL-322 trial, adding pirtobrutinib to a fixed course of venetoclax and rituximab raised 24-month progression-free survival to 87% from 72% in previously treated disease.

4 min read

THE DRUG DOCKET

A second BCL-2 blocker clears FDA for mantle-cell lymphoma on response alone

Beqalzi (sonrotoclax) is approved for relapsed mantle-cell lymphoma after a BTK inhibitor. Just over half of 103 patients responded in a single-arm trial with no survival data.

3 min read

This page indexes this newspaper’s reporting on Venetoclax. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.